BeiGene looks be­yond Chi­na as it se­cures new API source, nears open­ing of US site

With many bio­phar­ma com­pa­nies au­dit­ing their man­u­fac­tur­ing sup­ply chains, BeiGene will soon ac­ti­vate a sec­ond API sup­pli­er out­side of Chi­na and will al­so of­fi­cial­ly open its $800 mil­lion bi­o­log­ics pro­duc­tion fa­cil­i­ty in the US in Ju­ly.

“We are near­ing com­ple­tion of full qual­i­fi­ca­tion for a sec­ond API sup­pli­er that will soon be ac­tive. We are con­fi­dent with our cur­rent sup­ply of API and are well po­si­tioned for the fu­ture,” a BeiGene spokesper­son told End­points News, but de­clined to com­ment on time­lines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER